| Date | Title | Description |
| 02.04.2024 | Lumira Ventures Announces Investment in Nocion Therapeutics to Revolutionize Chronic Cough Treatment | TORONTO, ON / ACCESSWIRE / APRIL 2, 2024 / Lumira Ventures is delighted to announce its latest investment in Nocion Therapeutics, a clinical-stage biopharmaceutical company developing first and potentially best-in-class, small molecule char... |
| 19.03.2024 | Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer | HAMILTON, ON and BOSTON, March 19, 2024 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Com... |
| 11.03.2024 | Alexza completes acquisition of Symphony Allegro after sharholders' approval
AZoM.com powered by Azthena AI | - |
| 07.03.2024 | Lumira Ventures Celebrates Team Promotions, Emphasizes Growth and Development and Honors Female Contributions Ahead of International Women’s Day | TORONTO, ON / ACCESSWIRE / March 7, 2024 / Lumira Ventures, a life sciences investment firm dedicated to supporting healthcare innovation and patient impact, is proud to announce several significant advancements and promotions within its in... |
| 20.02.2024 | Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments | Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the Wnt/beta-catenin signaling pathway, announced today it is actively... |
| 14.02.2024 | enGene Announces Oversubscribed $200 Million Private Placement Financing | Financing included participation from new and existing investors
Pro forma cash and cash equivalents expected to fund current operating plan into 2027
enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage geneti... |
| 13.02.2024 | Transposon Announces Final Results from a Phase 2 Study of its LINE-1 Reverse Transcriptase Inhibitor TPN-101 for the Treatment of Progressive Supranuclear Palsy and Interim Results from a Phase 2 Stu... | TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP
Participants treated with TPN-101 for the entire 48-week study in PSP showed a stabilization of their clinica... |
| 01.02.2024 | Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study | A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System in Adult Patients with Type 2 Diabetes
Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients ... |
| 30.01.2024 | COUR Pharmaceuticals Secures $105 Million in Series A Financing Co-Led by Lumira Ventures and Alpha Wave Ventures | CHICAGO, Jan. 30, 2024 (GLOBE NEWSWIRE) — COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of first-in-class, disease modifying therapies designed to induce antigen-specific tolerance for immune-mediated... |
| 16.01.2024 | Cyrano Therapeutics Secures $9.0 Million Series B Financing to Advance Clinical Development of CYR-064 for Treatment of Post-Viral Smell Loss | Phase 2 FLAVOR clinical trial currently enrolling 150 patients to assess the safety and effectiveness of CYR-064 in treating patients with chronic smell loss following recovery from a viral infection (post-viral hyposmia) |
| 09.01.2024 | World’s First Patients Treated With Novel Edison® Histotripsy System | HistoSonics, (www.histosonics.com), the manufacturer of the non-invasive Edison® Histotripsy System, announced today a patient from the University of Rochester Medical Center has received the world’s first targeted liver tumor treatments ut... |
| 29.11.2023 | AmacaThera Closes Series A Extension to Advance Clinical Development of Long Acting, Localized, Non-Opioid Therapeutics to Improve Post-Surgery Patient Care | AmacaThera, a leader in the development of novel injectable, localized therapeutics based upon its AmacaGel delivery platform, announced the closing of a CAD$4.0 million financing round, with a new lead investor, supported by existing inves... |
| 21.11.2023 | Summer 2024 Analyst Position Open | Looking to make your mark in the world of venture capital and life sciences innovation? Lumira Ventures is accepting applications for exceptional business students to join our team as a Summer Analyst. By working hand in hand with seasoned ... |
| 02.11.2023 | Lumira Ventures Portfolio Company enGene (Nasdaq: ENGN) Debuts as Publicly Traded Genetic Medicines Company | CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansion |
| 17.10.2023 | Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors | Specific Biologics Inc. (“Specific”), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Steven Kanner, PhD, as an Independent Director. Dr. Kanner joins Brent Stead, PhD, MBA, as well as seasoned ... |
| 12.10.2023 | Cyrano Therapeutics Enrolls First Patient in Phase 2 Trial of CYR-064 for Post-Viral Smell Loss (Hyposmia) | There is currently no FDA-approved therapy for this increasingly prevalent and serious chronic sensory condition. |
| 12.10.2023 | Life Sciences BC Announces Companies and Mentors for Fourth Annual Investor Readiness Program | Life Sciences BC welcomes the companies and mentors participating in its 2024 Investor Readiness Program (IRP). Through a focused six-month program, small and mid-size enterprises (SMEs) in British Columbia’s life sciences sector are paired... |
| 12.10.2023 | Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government | Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical s... |
| 11.10.2023 | Endotronix Receives IDE Approval for the Market Expanding PROACTIVE-HF 2 Clinical Trial | Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), announced it has received Investigational Device Exemption (IDE) approval from the FDA for a subsequent multicente... |
| 10.10.2023 | OpSens, Inc Acquired by Haemonetics for $345 Million | Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused comp... |
| 10.10.2023 | FDA Awards HistoSonics Clearance of its First-of-a-Kind Edison® Histotripsy System | HistoSonics®, (www.histosonics.com), the manufacturer of the Edison® System and novel histotripsy therapy platforms, announced today the marketing authorization of its “Breakthrough” platform via the U.S. Food and Drug Administration’s (FDA... |
| 28.09.2023 | Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact | Sept. 28, 2023 — Maryland-based biotech company Deka Biosciences (“Deka”) today announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by a... |
| 07.09.2023 | enGene Appoints Richard Bryce, MBChB, MRCGP, MFPM, as Chief Medical Officer | enGene, Inc., a clinical-stage biotechnology company mainstreaming gene therapy through its novel platform for the delivery of therapeutics to mucosal tissues and other organs, today announced the appointment of Richard Bryce, MBChB, MRCGP,... |
| 28.08.2023 | Molly Shoichet Joins PRIME as New Scientific Director for Precision Medicine Initiative | AmacaThera Co-Founder, Chief Scientific Officer and University Professor Molly Shoichet is the new Scientific Director of PRiME Next-Generation Precision Medicine, a University of Toronto (U of T) Strategic Initiative based at the Leslie Da... |
| 23.08.2023 | Fall 2023 Lumira Venture Innovation Program (VIP): Venture Fellow Applications Open | Looking to make a career in life sciences innovation? Our Venture Innovation Program (VIP) is accepting applications for exceptional students across Canada who want to gain exposure to life sciences venture capital and start-ups, and are co... |
| 15.08.2023 | Thryv Therapeutics announces FDA clearance for Phase 1 Study of THRV-1257 in Anaplastic Thyroid Cancer and acceptance of Late-Breaking Poster Presentation at American Thyroid Association Meeting. | Montreal, Quebec – August 15, 2023 – Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome (LQTS), atrial fibrillation, and resistant cancers, announced ... |
| 13.06.2023 | A 5-Year, $50k Pledge: Supporting Mélanie’s Way on Their Mission to Impact the Lives of Women with Metastatic Cancer and Their Families | Mélanie’s Way is a Canadian charity dedicated to granting personalized ‘wishes’ to send women battling cancer and their families on trips of a lifetime. The mission was inspired by Mélanie Chalmers who refused to be defined by the cancer th... |
| 13.06.2023 | DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer | TORONTO, June 13, 2023 — DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain... |
| 24.05.2023 | Managing General Partner, Peter van der Velden Wins the 2023 Barry Gekiere Lifetime Legacy Award | Throughout his more-than-30-year career, Peter van der Velden’s focus has not only been on investing, but also on making a lasting impact in healthcare. Although he initially contemplated becoming a doctor, he soon realized that he was more... |
| 23.05.2023 | Endotronix Extends Positive Outcomes with 12-month Data Release from the SIRONA 2 Trial for Remote Heart Failure Management Using the Cordella Pulmonary Artery Sensor | The study met secondary study endpoints and long-term sensor use was associated with significant improvements in patient quality-of-life metrics and low event rates for heart failure hospitalization and death. |
| 23.05.2023 | Cadence Neuroscience Secures $26 Million in Series B Financing for Clinical Trials of Epilepsy Neuromodulation Therapy | Cadence Neuroscience announced that it has secured $26 million in Series B financing. The round was led by Angelini Lumira Biosciences Fund (co-managed by Lumira Ventures and Angelini Ventures) and included other new investors F-Prime Capit... |
| 27.04.2023 | Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO | Proceeds to Support Key Efficacy Studies for ABI-2280 including Phase 2 Trial in High-Grade Cervical Intraepithelial Neoplasia (CIN 2,3) and Exploratory Study as Treatment for High-Risk HPV Infections |
| 19.04.2023 | PIC Therapeutics Presents Pre-Clinical Data Update on eIF4E Regulators at AACR Annual Meeting 2023 | PIC Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-mechanism, first-in-class allosteric small molecule therapies targeting eIF4E, is presenting pre-clinical data today on the company’s advan... |
| 12.04.2023 | Fusion Pharmaceuticals Announces IND Clearance For FPI-2068, A Jointly Developed Novel Targeted Alpha Therapy | Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the clearance of investigational new drug (IND) applications fo... |
| 10.04.2023 | Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets | Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on validated targets in cancer and inflammatory disease, today announced it has entered into a Research Col... |
| 06.04.2023 | Deka Biosciences Announces First-in-Human Dose in Phase 1 Clinical Trial of DK210 (EGFR) | Deka Biosciences (“Deka”), a clinical-stage biotechnology company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced today that the first subject has been dosed in a Phase 1 clinical trial of... |
| 05.04.2023 | OpSens Announces 1,000th SavvyWire Procedure | OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, announced a significant milestone for the Company as... |
| 05.04.2023 | Endotronix Announces Enrollment Completion of PROACTIVE-HF Pivotal Trial | Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced its PROACTIVE-HF pivotal study successfully completed enrollment. Designed to evaluate the safety ... |
| 05.04.2023 | HistoSonics Announces First Ever Kidney Tumor Treatment Using Histotripsy | HistoSonics, (www.histosonics.com), the developer of a non-invasive platform and novel sonic beam therapy called histotripsy, announced today the first kidney patient has been treated using the Company’s histotripsy platform. The procedure ... |
| 06.03.2023 | Congruence Therapeutics Announces Close of Series A Extension, Bringing Total Round to Over US$65 Million | Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the close of an extension to its ... |
| 28.02.2023 | Rare Disease Day 2023 | Today, February 28th, 2023, is Rare Disease Day. Celebrated internationally, the day is an opportunity to raise awareness and advocate for rare diseases as a human rights priority and work towards a more inclusive society. Over 300 million ... |
| 19.02.2023 | Pharmasset Initiates Phase 2a Trial with PSI-7977, a Chirally Pure Isomer of PSI-7851 | - |
| 08.02.2023 | 2023 Lumira Venture Innovation Program (VIP): Fellow and Summer Analyst Applications Open | Looking to make a career in life sciences innovation? Our Venture Innovation Program (VIP) is accepting applications for exceptional students across Canada who want to gain exposure to life sciences venture capital and start-ups, and are co... |
| 26.01.2023 | XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina | No serious adverse events related to drug product were reported
Patients demonstrated improvements in exercise capacity and reductions in episodes of chest pain
Cardiac imaging results provide mechanistic evidence supporting the therapeutic... |
| 18.01.2023 | Cyrano Therapeutics Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of CYR-064 to Treat Post-Viral Smell Loss (Hyposmia) | Currently no FDA-approved therapy for this serious condition |
| 05.01.2023 | Cardiac Dimensions Raises $35 Million in Series D Financing | Funds Expected to Support Enrollment in U.S. Pivotal EMPOWER Trial and European Commercial Expansion for Carillon Mitral Contour System®. |
| 05.01.2023 | AmacaThera’s Lung Cancer Applications Recognized in QuickFire Challenge | AmacaThera, a clinical-stage biotechnology company developing advanced injectable biomaterials for local, sustained delivery of oncology and pain therapeutics, has received grant funding from the Innovations for Vets QuickFire Challenge: Lu... |
| 03.01.2023 | Deka Biosciences, Inc Announces Submission of Investigational New Drug (IND) Application for Lead Oncology Asset, DK210 (EGFR) | Important Regulatory Milestone Provides Runway to Move DK210 (EGFR) into the Clinical Phase |
| 03.01.2023 | FDA Grants Fast Track to Edesa Biotech’s ARDS Drug Candidate | Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients. |
| 13.12.2022 | HistoSonics Announces $100 Million in Financings and New Appointment to its Board of Directors | Financings Planned to Support Rapid Expansion of Histotripsy Platform as Company Welcomes Silk Road Medical CEO, Erica Rogers, to its Board of Directors |
| 24.11.2022 | World Antimicrobial Awareness Week 2022 | Antimicrobial resistance (AMR) occurs when microbes (bacteria, viruses, fungi and parasites) change over time and evolve mechanisms that protect them from the effects of antimicrobials. This process results in microbes no longer responding ... |
| 08.11.2022 | Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. As Chief Medical Officer | Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Dmitri Bobilev, M.D., as chief medical offic... |
| 27.10.2022 | Unknown Error. | - |
| 19.10.2022 | Lumira Ventures Participates In The Closing of PIC Therapeutics $35 Million Series A Financing to Develop Treatments for Drug-Resistant Breast Cancer | October 19, 2022 – PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, today announced the closing of a $35 million Series A financing led by OrbiMed. Other new inves... |
| 10.10.2022 | World Mental Health Day 2022 | In 2021, Lumira Ventures and Angelini Pharma launched the Angelini Lumira Biosciences Fund (ALBF) to invest in early-stage companies in Canada and U.S. markets that are developing pharmaceutical therapies for central nervous system disorder... |
| 26.09.2022 | DAMONA Pharmaceuticals Raises US$5.5 Million Seed Stage Financing to Advance Lead Molecule Development to Treat Cognitive Deficits Associated with Depression and Diseases of Aging | TORONTO, Ontario, September 26, 2022 — DAMONA Pharmaceuticals today announced the closing of a seed stage financing round to support the development of its lead therapeutic for the treatment of cognitive symptoms associated with depression ... |
| 13.09.2022 | A Look Around The Corner For Life Sciences: Nikhil Thatte Speaks at the 2022 Atlantic Venture Forum | Tomorrow, Tuesday, September 13th, 2022 at 3 pm ET, Lumira Ventures Principal, Nikhil Thatte will be presenting as the keynote speaker for the 2022 Atlantic Venture Forum (AVF). The AVF is the largest annual convergence of industry leaders,... |
| 09.09.2022 | Deka Biosciences Appoints Chief Medical Officer and Vice President of Clinical Operations | GERMANTOWN, Md., Sept. 8, 2022 /PRNewswire/ — Deka Biosciences (“Deka”), a biotech company focused on the development of novel cytokine therapies to treat cancer and inflammatory diseases, announced today the appointment of Charlotte Moser,... |
| 22.08.2022 | 2022 Lumira Venture Innovation Program (VIP): Fall Cohort Applications Open | The Venture Innovation Program is a 6-12 month program for Ph.D., MBA, and MD students across Canada who want to gain exposure to life sciences venture capital and start-ups, and are committed to pushing the future of life sciences innovati... |
| 02.08.2022 | Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine | Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, to... |
| 27.07.2022 | Summer Office Hour Registration is Open! | Lumira Ventures is excited to present our 2022 Office Hours beginning this August! Every Wednesday from 4:00 – 5:00 PM ET, Associates Baye Galligan and Suman Rao will be available to chat with members of our community and answer any questio... |
| 26.07.2022 | X4 Pharmaceuticals Announces $55 Million Private Placement Financing and Debt Facility Amendment Extending Interest-Only Period by up to 12 Months | X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4 targeted small molecule therapeutics to benefit people with rare immune system disorders, today announced that it has agreed to sell an aggreg... |
| 21.07.2022 | Nikhil Thatte, Hosts the 2022 Life Science Future – Medtech, Investor Reverse Pitch Event | Thursday, July 21st, 2022 at 1 pm ET, Lumira Ventures Principal, Nikhil Thatte hosts the Investor Reverse Pitch Presentation at the 2022 Life Science Future – Medtech Conference. Life Sciences Future – MedTech is an annual event focused on ... |
| 11.07.2022 | Expanding Pipeline Leads to Name Change – LQT Therapeutics Now Thryv Therapeutics | LAVAL, Québec, Canada | 11 July 2022 | Thryv Therapeutics Inc. is excited to announce the evolution of its portfolio to include treatments for resistant and rare cancers. The new name, Thryv Therapeutics Inc., embodies our commitment to rel... |
| 28.06.2022 | Paused | - |
| 28.06.2022 | XyloCor Therapeutics Achieves Target Enrollment in Phase 2 EXACT Study of XC001 Novel Gene Therapy for Ischemic Heart Disease | XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced it has achieved enrollment of target number of subjects in the Phase 2 portion of its ongoing Phase... |
| 24.06.2022 | Medexus Generates Revenue of US$76.7 Million in Fiscal Year 2022 and US$20.3 million in Fiscal Q4 (Strongest Q4 Revenue in Company History) | Medexus Pharmaceuticals (Medexus) (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company’s fourth fiscal quarter and fiscal year ended March 31, 2022. All dollar amounts ... |
| 15.06.2022 | Lumira Ventures Builds Upon Presence in Western Canada with Partner Lu Han, Ph.D. Expanding Firm’s Vancouver Office | TORONTO, Ontario, June 14, 2022 — Lumira Ventures, a global healthcare venture capital firm, announced today that Partner Lu Han Ph.D. has relocated to the firm’s office in Vancouver, British Colombia. Dr. Han will expand upon Lumira Ventur... |
| 14.06.2022 | Corvia Medical Closed $54 Million Financing to Support Planned Confirmatory Trial of the Corvia® Atrial Shunt | Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients |
| 07.06.2022 | Lumira Ventures Announces Appointment of David Novak as Venture Partner | Accomplished Biotechnology Industry Equity Analyst Will Support Firm’s Public Market Investment Initiatives |
| 06.06.2022 | G1 Therapeutics Presents Promising Trilaciclib Data at ASCO | Data Presented at ASCO Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Patients Prior to Chemotherapy |
| 01.06.2022 | HistoSonics Hits Pivotal Clinical Trial Milestone In #HOPE4LIVER Studies | Company Continues to Build as It Prepares for FDA Submission and Clearance of Its Breakthrough Therapy |
| 27.05.2022 | Lumira Ventures is Looking for a Controller to Join Our Team | Lumira Ventures is an impactful investor and you will share our passion for innovation and being part of a team-building transformative companies. We are a venture capital organization investing capital on behalf of our investors to build b... |
| 26.05.2022 | Nikhil Thatte Hosts Invest Canada 2022: Investing in Life Sciences From Health Tech to Therapeutics Panel Discussion | This Thursday, May 26th, 2022, join Lumira Ventures Principal, Nikhil Thatte as he leads the Investing in Life Sciences from Health Tech to Therapeutics: Driving Impact and Producing Sizable Returns panel discussion. Nikhil along with four ... |
| 24.05.2022 | HistoSonics Announces Agreement with GE Healthcare | MINNEAPOLIS, May 23, 2022 — HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agreement formalizing ongoing efforts to use GE Healthcare’s LOGIQ E10 Series ultrasound imag... |
| 18.05.2022 | XyloCor Therapeutics Presents Preliminary Clinical Data from Phase 1 Portion of the EXACT Phase 1/2 Study of XC001 Novel Gene Therapy for Refractory Angina | Wayne, PA, May 18, 2022 — XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced presentation of initial clinical data from the Phase 1 portion of its ong... |
| 11.05.2022 | Alice Luo Presents Lumira Ventures at the 2022 Life Sciences Career Expo | On Wednesday, May 11th, 2022, Lumira Ventures Analyst, Alice Luo will represent Lumira during her company spotlight presentation for the Life Sciences Career Expo: Starting Your Career Journey. The event is a national, multi-day conference ... |
| 10.05.2022 | Suman Rao Serves as a Business Mentor For The McGill Invention to Impact Training Program | Beginning May 2, 2022 until July 13, 2022, Lumira Ventures Associate, Suman Rao will act as a business mentor to one of the participating teams at the McGill Engine’s Invention to Impact program. Through the duration of the program, Suman w... |
| 04.04.2022 | Nikhil Thatte Speaks at the Open for Business Ontario: Life Sciences Innovation Series | Wednesday, April 6th, 2022, Lumira Ventures Principal, Nikhil Thatte speaks on a panel of industry leaders at the Open for Business Ontario: Life Sciences Innovation Series webinar. During the event, Nikhil provides insight into the industr... |
| 14.03.2022 | 2022 Lumira Venture Innovation Program Information (Lumira VIP) | The Venture Innovation Program is a 6-12 month program for Ph.D., MBA, and MD students across Canada who want to gain exposure to life sciences venture capital and start-ups, and are committed to pushing the future of life sciences innovati... |
| 08.03.2022 | Celebrating The Inspirational Women of Lumira Ventures: International Women’s Day 2022 | Every year on March 8th, we observe International Women’s Day by honoring the social, political, economic, and cultural achievements of women globally. Additionally, the day marks a call to action for accelerating gender parity. This year’s... |
| 02.03.2022 | OncoMyx Appoints Robert Williamson Chief Business and Chief Financial Officer | OncoMyx Therapeutics, a privately-held oncolytic virus immunotherapy company, today announced the appointment of Robert Williamson as Chief Business and Chief Financial Officer. Mr. Williamson has more than two decades of experience in buil... |
| 28.02.2022 | Rare Disease Day 2022 | Today is Rare Disease Day and we at Lumira Ventures are proud of our ongoing commitment to supporting the discovery, development and commercialization of innovative therapeutic products with the potential to materially impact the lives of p... |
| 24.02.2022 | Peter van der Velden Talks All Things VC on the McRock Live Podcast | This Friday February 25th, Join Lumira Ventures Managing General Partner, Peter van der Velden for a live podcasting event hosted by McRock Capital. On this episode of McRock LIVE, Peter will be having a discussion with Chris Arsenault, Ino... |
| 08.02.2022 | enGene Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer | enGene Inc., a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues enabled by its proprietary DDX platform, today announced positive results from its LEGEND study, a f... |
| 08.02.2022 | Congruence Therapeutics Inc. Announces US$50 million Series A Financing to Advance Platform Targeting Diseases of Protein Misfolding | Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding, announced today the closing of a US$50 million, t... |
| 03.02.2022 | Peter van der Velden is the Keynote Speaker and Panelist at the 9th Annual Falcons’ Fortunes Pitch Competition | On Friday, February 4th, Lumira Ventures General Partner and Managing Director, Peter van der Velden will be presenting as a keynote speaker and panelist judge for FACIT’s 9th annual Falcons’ Fortunes Pitch Competition. A day showcasing six... |
| 18.01.2022 | XyloCor Therapeutics Expands Leadership Team with Accomplished Pharmaceutical Executives to Accelerate Clinical Development Programs and Drive Corporate Growth | XyloCor Therapeutics, a clinical‑stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced that it has appointed Elizabeth Tarka, M.D. as Chief Medical Officer and A. Brian Davis as Chief Fi... |
| 13.01.2022 | Edesa Biotech Receives Canadian Approval to Test COVID-19 Drug as Rescue Therapy | Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that the company has received approval from Health Canada to test its monoclonal antibody cand... |
| 11.01.2022 | LQT Therapeutics Announces Collaboration with Leading Cancer Researcher | LQT Therapeutics, Inc. (“LQTT”) is pleased to announce a collaboration with the laboratory of Dr. Donald McDonnell of Duke University School of Medicine to evaluate LQTT SGK1 inhibitors as potential treatment for patients with resistant pro... |
| 10.01.2022 | Fusion Pharmaceuticals Announces Nomination Of First Targeted Alpha Therapy Candidate In Collaboration With AstraZeneca To Advance Into IND-Enabling Studies For Phase 1 Development | Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced nomination of the first targeted alpha therapy (TAT) candidate ... |
| 06.01.2022 | LQT Therapeutics Announces Award by the European Joint Program for Rare Diseases for SGK1 inhibition as a novel therapeutic approach in Long QT Syndrome | Closing the gap between industry and academia to place patients directly at the center of research efforts. |
| 06.01.2022 | Lumira Ventures Announces Promotion of Lu Han, Ph.D. to Partner and Team Expansion | TORONTO, January 6, 2022 – Lumira Ventures, a leading North American healthcare venture capital firm, today announced the promotion of Dr. Lu Han, Ph.D., to Partner and the appointments of Dr. Suman Rao, Ph.D. as an Associate and Dr. Ai Li ... |
| 06.01.2022 | Antiva Biosciences Named Winner of Global Women’s HealthTech Award By World Bank Group and Consumer Technology Association | Honor Recognizes Companies Advancing Innovative Solutions to Improve Women’s Health and Safety in Emerging Markets |
| 05.01.2022 | Endotronix Announces FDA Approval for PROACTIVE-HF Pivotal Trial Design Change to Single-Arm Study | Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the U.S. Food and Drug Administration (FDA) has granted approval for an amendment to the company’s... |
| 16.12.2021 | Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations | Specific Biologics Inc. (“Specific”) today announced that it has closed its first institutional financing, led by Lumira Ventures and adMare BioInnovations which have recently established an innovative partnership to build Canadian life sci... |
| 14.12.2021 | Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus In... | Antios Therapeutics, Inc. (“Antios”) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A sing... |
| 13.12.2021 | OpSens Announces 510(K) Submission to U.S FDA for New Guidewire for the TAVR Procedure | OpSens Inc. (“OpSens” or the “Company”) (TSX: OPS) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has filed a 510(k) submissio... |
| 08.12.2021 | Lumira Co-Leads OncoMyx $50 Million Series B to Advance a Novel Immuno-Oncology Platform that Delivers Multiple Cancer-Killing Payloads | OncoMyx Therapeutics, a privately-held immuno-oncology platform company, today announced the closing of a $50 million Series B financing, co-led by Lumira Ventures and B Capital Group with participation from LYZZ Capital and all Series A in... |
| 07.12.2021 | Suman Rao Speaks as an Investor Judge at the 2021 Venture Summit Virtual Connect | Join Lumira Ventures, Associate, Suman Rao for the 2021 Venture Summit Virtual Connect. The summit brings together leading innovators and investors across various fields including life science / healthcare to connect and network virtually. ... |